A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether remote ischaemic preconditioning (RIPC) is of benefit to patients undergoing cardiac surgery. Altogether, more than 264 papers were found using the reported search, 16 of which represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We conclude that RIPC is a safe protocol which could potentially be used in cardiac surgery to provide additional cardiac protection against ischaemia reperfusion injury, although it may not be appropriate for patients on K + ATPase channel blockers (sulphonylureas) as they seem to eliminate the effect of RIPC. In our study, we found two meta-analyses of cardiac surgery with or without RIPC. Both unequivocally showed 0.81 and 0.74 standardized mean reduction in myocardial necrosis markers in patients receiving RIPC and cardiac or vascular surgery. No difference in perioperative myocardial infarction incidence or 30-day mortality were found. In adult cardiac surgery, we found 11 randomized control trials (RCTs) ranging in size from 45 to 162 patients. Two representative studies reported no difference in postoperative cardiac troponin I concentration in RIPC vs. controls. In one of the studies (CABG ± RIPC) no additional benefit could have been observed for RIPC regarding intra-aortic balloon pump usage (controls 8.5 vs. RIPC 7.5%), inotropic support (39 vs. 50%) or vasoconstrictor usage (66 vs. 64%). On the other hand, in the other study [CABG ± AVR (aortic valve replacement) ± RIPC] significant reduction of troponin I at 8 h postoperatively (controls, 2.90 µg/l vs. RIPC, 2.54 µg/l, P = 0.043) was shown. Marked reduction in cardiac necrosis markers was also found in several smaller RCTs concerning coronary artery bypass grafting (CABG) patients receiving RIPC preoperatively: with cold crystalloid cardioplegia (44.5% reduction), with cross-clamping and fibrillation (43% reduction) and with cold blood cardioplegia (42.4% reduction). The proof of concept trials summarized here give some early evidence that RIPC may potentially provide some reduction in myocardial injury. If confirmed, in future clinical studies this technique may one day lead to a method to reduce reperfusion injury in clinical practice.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
You are reviewing a 68-year old accountant who underwent emergent coronary artery bypass grafting (CABG) overnight. He has developed a low cardiac output syndrome. After reviewing the patient's data you see that he had cold blood cardioplegia every 20 min with warm induction and also a 'hot shot' at the end. You conclude that this was the best possible myocardial protection strategy that could have been used so you wonder whether in addition RIPC, a novel method for cardiac protection, added to the regular cardioprotective protocol, would have improved his postoperative myocardial function. Therefore, you resolve to check the literature yourself. 
SEARCH OUTCOME
Two hundred and sixty four papers were found using the reported search. Sixteen papers were identified that provided the best evidence to answer the question. These are presented in Table 1 . Two meta-analyses and 14 randomized controlled trials were found to be the most representative to address the question.
RESULTS
Two meta-analyses performed by the same group (Takagi et al.) in 2008 and 2011 included cardiac and vascular surgery trials [2, 3] . First meta-analysis of four RCTs of RIPC vs. controls gathered 184 subjects, 82 of whom were abdominal aortic aneurysm patients and remaining in coronary and paediatric cardiac surgery [2] . This pooled analysis showed 0.81 standardized mean reduction of myocardial necrosis markers in patients receiving RIPC. In 2011, an updated pooled analysis included nine RCT's of 482 patients undergoing cardiac or vascular surgery [3] . No difference in perioperative myocardial infarction or in-hospital mortality (30 days postoperatively) were found between RIPC and controls. The 2011 update showed the standardized mean reduction of 0.74 in myocardial necrosis markers among patients receiving RIPC.
Rahman et al. provided contrasting findings in a randomized controlled trial [4] . By prospective random allocation of 162 patients, either to isolated CABG and RIPC or CABG alone, the author did not show a single effect in postoperative haemodynamic functioning of patients submitted to RIPC nor did he observe a reduction in the total cTnI area under the curve (AUC) after 48 h. Additionally, no further benefit could have been observed for RIPC regarding intra-aortic balloon pump usage (controls, 8.5 vs. RIPC, 7.5%), inotropic support (39 vs. 50%), vasoconstrictor usage (66 vs. 64%), postoperative dialysis requirement (1.2 vs. 3.8%) and intubation time (median, 938 vs. 895 min). This study used the longest interval between RIPC protocol and aorta cross-clamping, with the anaesthesia being maintained by volatile anaesthetics such as isoflurane or enflurane, which might have been the reason for these negative results. Wagner et al. [5] used crystalloid cardioplegia and RIPC for cardiac protection in the adult patients suffering from triple vessel coronary artery disease with or without clinically significant aortic valve disease. In this group, the benefit from the RIPC has been documented by means of cTnI level reduction at the 8th h postoperatively [ Table 1 .]. The above mentioned data are consistent with the findings of Hausenloy et al. [6] and Venugopal et al. [7] , who in their aptly designed trials involving CABG patients provided the evidence of nearly 43 and 42.4% reduction of the total postoperative troponin I in patients receiving RIPC. Ali et al. [8] , in his study of coronary bypass adult population, found RIPC to provide enhanced protection by means of CKMB level reduction at the 8th, 16th and 48th h postoperatively. Thielmann et al. [9] went further to demonstrate the effect of RIPC in coronary artery bypass patients operated on with the use of cold crystalloid cardioplegia. In his study AUC, after 72 h postoperatively, indicated a reduction of total troponin I by 44.5%. Hong et al.
[10] in a study of patients undergoing off-pump surgery showed a reduction of 23% of total troponin I, although this was not statistically significant after 72 h postoperatively. The author hypothesized that this might have been due to a low reperfusion injury associated with off-pump CABG in general. Only two studies concerning RIPC in isolated cardiac valve surgery have been carried out so far. Li et al. studied potential effects of RIPC and perconditioning (i.e. three 5 min long intervals of lower limb ischaemia and reperfusion, starting once the aorta is being crossclamped) in adult patients submitted to heart valve surgery [11] . This RCT enrolled diabetic patients who were more likely to receive sulphonylureas, K+ ATPase channel blockers, which can abolish the effect of remote preconditioning and therefore their results should be approached with caution. Wu et al. found that patients submitted to mitral valve replacement could benefit from RIPC by the reduction of troponin I concentration and lower dobutamine support requirements postoperatively [12] . Three RCTs were designed in order to study the effect of RIPC in paediatric patients submitted to cardiac surgery. Two studies of Luo et al. [13] and Zhou et al. [14] , having been the most representative so far, showed lower cardiac injury by means of troponin I and CK-MB reduction as well as lower requirement for postoperative dobutamine support in patients receiving RIPC.
There was no study reporting any RIPC-related side effects or a negative outcome in RIPC group during cardiac surgery.
CLINICAL BOTTOM LINE
The proof of concept trials summarized here give some early evidence that RIPC may potentially provide some reduction in myocardial injury. If confirmed, in future clinical studies this technique may one day lead to a method to reduce reperfusion injury in clinical practice.
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